XBiotech annonce la nomination de Sushma Shivaswamy et Jan-Paul Simard aux postes de co-directeurs généraux

XBiotech Inc. (NASDAQ: XBIT) announced the appointment of Jan-Paul Simard as Co-Chief Executive Officer alongside Dr. Sushma Shivaswamy, effective October 23, 2026. Dr. Shivaswamy, who has been with the company for 17 years and served as interim CEO following the founder's retirement, will now share leadership responsibilities with Simard, who joined XBiotech in 2012 and has contributed to clinical trial development across multiple therapeutic areas.

10/24/2026, 8:07 AM • GlobeNewswire

XBiotech gibt die Wahl von Sushma Shivaswamy und Jan-Paul Simard zu Co-Chief Executive Officers bekannt

XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside Dr. Sushma Shivaswamy, effective October 23, 2026. Dr. Shivaswamy, who has been with the company for 17 years and served as Interim CEO since December 2025, will now share leadership responsibilities with Simard. The co-CEO structure aims to leverage their complementary skills and scientific expertise to advance the company's true Human antibody therapies across oncology, inflammatory diseases, and infectious diseases.

10/24/2026, 8:07 AM • GlobeNewswire

XBiotech annonce des résultats d’efficacité finaux positifs de phase II pour l’essai TASKIN commandité par un chercheur dans le cancer colorectal métastatique réfractaire

XBiotech announced positive Phase II results for its anti-IL-1α monoclonal antibody vilamakitug (Natrunix) in treating refractory metastatic colorectal cancer. The investigator-sponsored TASKIN trial met its primary efficacy endpoint with 61.3% 12-month overall survival in the treatment arm versus 55.7% in the control arm. Notably, exploratory analysis showed a statistically significant 62% reduction in death risk for right-sided colon tumors, a historically aggressive subtype with high unmet medical needs.

10/19/2026, 6:59 PM • GlobeNewswire

XBiotech gibt positive endgültige Wirksamkeitsergebnisse der Phase-II-Studie „TASKIN“ bekannt, einer von Forschern initiierten Studie zur Behandlung von refraktärem metastasiertem Kolorektalkarzinom

XBiotech announced positive final efficacy results from the Phase II TASKIN trial of its anti-IL-1α monoclonal antibody Vilamakitug (XB2001) combined with standard chemotherapy for refractory metastatic colorectal cancer. The study met its primary efficacy endpoint with a 12-month overall survival rate of 61.3% versus 55.7% in the control group. An exploratory subgroup analysis showed a statistically significant 62% reduction in mortality risk for patients with right-sided tumors.

10/19/2026, 6:59 PM • GlobeNewswire

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

XBiotech announced positive Phase II results from the TASKIN trial showing its anti-IL-1α monoclonal antibody vilamakitug (XB2001) met primary efficacy criteria with 61.3% 12-month overall survival in refractory metastatic colorectal cancer patients. An exploratory analysis revealed significant survival benefits in right-sided tumors, with a 62% reduction in death risk compared to control.

10/19/2026, 9:00 AM • GlobeNewswire

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

XBiotech announced that its IND application for the V-SPINE Phase II clinical trial evaluating vilamakitug (an IL-1α antibody) for treating active axial spondyloarthritis has completed FDA review without a clinical hold. The double-blind, placebo-controlled study will enroll 150 participants and evaluate the drug's efficacy and safety, with the primary endpoint being ASAS40 response at Week 16.

06/15/2026, 9:00 AM • GlobeNewswire